Visgenx
San Diego
About Visgenx
Visgenx develops therapeutics to protect against the loss of sight from retinal disorders. Its programs are based on increasing the expression of a gene known as ELOVL2 which may regulate aging in cells critical for vision.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.5M
- Last round: Series Unknown (Jun 2023)
- Website: visgenx.com
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/visgenx-43146 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.